Articles tagged with Obesity
A low-calorie diet and behavioral support program significantly reduced weight in older patients with overweight and persistent atrial fibrillation at 8 months. The study found no safety concerns or impact on atrial fibrillation symptoms, cardiac remodeling, or need for further rhythm control interventions.
Researchers developed an AI framework, MouseMapper, to map disease-related changes in the entire mouse body. They found widespread inflammation and previously unrecognized damage to facial sensory nerves caused by obesity, which was also observed in human tissue.
Researchers identified a subgroup of patients who experience nearly twice the improvement in sleep apnea when treated with tirzepatide GLP-1. These strong responders have distinct characteristics, including severe upper-airway collapsibility and breathing control instability. The study aims to provide personalized treatment options for...
A new study published in eBioMedicine found that integrating measurements such as body fat percentage and waist circumference can help identify individuals at high risk of developing obesity-related diseases. The research team analysed data from 489,311 participants and found that those with an adverse adiposity profile despite normal ...
A research study, COACH trial, is testing different ways to help children and families improve their health through lifestyle changes delivered by primary care clinics. The study aims to assess the effectiveness of personalized nutrition counseling, community resources, and online interactive lessons on weight management.
A cohort study found a potential association between GLP-1 RA use and improved survival rates among obese breast cancer patients with related metabolic conditions. Further evaluation of GLP-1 RA therapy in randomized clinical trials is warranted based on these findings.
A new study found that obesity-related changes in body fat send harmful signals to the brain, disrupting brain immune function and worsening Alzheimer's pathology. Restoring balance in phosphatidylethanolamines reduced lipid dysregulation, improved brain function and cognitive performance in Alzheimer's disease models.
A study of 65 countries found that consuming food away from home is consistently associated with obesity. Eating out is driven by sociodemographic factors such as sex, age, income, and education, and is linked to higher energy intake and body mass index.
A new post-hoc analysis examined daily oral orforglipron treatment for obesity, with or without diabetes, in users aged 65 years and over. The study found that orforglipron significantly reduced body weight and improved blood sugar markers compared to placebo, with a similar safety profile to the overall ATTAIN clinical trial population.
A pooled analysis of trials reveals semaglutide's safety and efficacy in individuals aged 65 years and older with obesity. The study found significant reductions in body weight and improvements in cardiometabolic risk factors, with a lower proportion of adverse events compared to placebo.
A new study found that reducing annual working hours by 1% is linked to a small decline in obesity rates across 33 OECD countries, with the impact being stronger for men than women. Higher income levels and urbanization also showed significant correlations with lower obesity prevalence.
The 'Ozempic Era' suggests a paradigm shift in understanding obesity, blaming commercial food systems rather than individual failings. Emerging medical data on GLP-1 agonists may drive policy responses to regulate ultra-processed foods.
The summit brought together endocrine leaders to identify opportunities to work closely together on increasing the visibility of endocrine health in policy decisions. Early findings from a workforce survey revealed challenges including long patient waiting times and retention concerns among early-career clinicians.
A new study found that bariatric surgery offers significantly greater protection against major adverse cardiovascular events compared to GLP-1 drugs. After five years, surgical patients were nearly 16% less likely to develop heart attacks, strokes, and deaths compared to those treated with GLP-1 drugs.
A study published in Cancer Medicine reveals that the same genes active in pancreatic cancer are also linked to obesity and diabetes, driving inflammatory and immune pathways. This discovery helps explain poorer cancer outcomes for those with metabolic disease and offers new avenues for targeted treatment.
A large real-world study comparing bariatric surgery to GLP-1 drugs found that surgery produced significantly greater weight loss and higher rates of obesity-related disease remission. After 12 months, patients who underwent surgery achieved more than 20% greater weight loss than those treated with GLP-1 therapy.
A $10 million grant from the National Institute of Environmental Health Sciences will support research on PFAS health effects and translate discoveries into real-world solutions. The study aims to identify links between PFAS exposure and metabolic conditions, such as obesity and type 2 diabetes.
A European Society of Cardiology consensus report suggests that ultra processed food consumption is linked to cardiovascular disease and death. The report calls for doctors to advise patients on limiting UPF intake to prevent cardiovascular risks.
A real-world analysis of over 90,000 patients with obesity and type 2 diabetes reveals that metabolic and bariatric surgery is the more affordable treatment option compared to GLP-1 drugs. Total costs for GLP-1 therapy were $17,000 more than sleeve gastrectomy and $7,200 more than gastric bypass after two years.
New data show that over 50% of patients with obesity and CKD experienced a significant reduction in kidney failure risk, as well as a nearly 75% drop in mortality rate after undergoing bariatric surgery. This study highlights the transformative impact of metabolic and bariatric surgery on chronic disease outcomes.
The number of metabolic and bariatric surgery procedures in the US declined by over 20% between 2023 and 2024, falling below 200,000 for the first time since 2020. The decline is attributed to rising obesity rates and increased use of GLP-1 medications, with significant shifts seen in the types of operations being performed.
Patients treated with GLP-1 drugs before surgery lost more weight than those who went directly to surgery, with total weight loss increasing to over 25% after gastric bypass and 20% after sleeve gastrectomy.
A recent analysis found that GLP-1 prescriptions have grown exponentially, while bariatric surgery procedures have declined in recent years. The study revealed that over 90% of patients with severe obesity receive no treatment, highlighting the need for increased access to weight-loss therapies.
A review from Florida Atlantic University links obesity to Alzheimer's disease through disruptions in metabolism, highlighting the importance of mitochondrial function and gut-brain axis balance. Early detection and whole-body prevention may become possible through monitoring metabolic health.
A National Institutes of Health grant supports Mary Elizabeth Baugh's research into how metabolic health influences brain systems that shape eating behaviors. The study aims to understand the interactions between metabolic signals and brain circuits engaged in everyday learning and eating behavior.
A new tool can predict an individual's risk of developing 18 obesity-related diseases, identifying those at highest risk for earlier intervention. The OBSCORE model uses 20 commonly collected health measures to provide a more accurate and personalized way to identify individuals at higher risk.
Researchers found that NRG4, an adipokine secreted by white adipose tissue, suppresses breast cancer metastasis via ERBB4-YAP1 signaling. The study also showed that higher NRG4 levels correlate with improved patient survival outcomes.
A new approach for treating obesity and type 2 diabetes has been developed using a hybrid molecule that targets specific cells. The treatment combines the well-known GLP-1/GIP signalling pathway with an additional metabolic modulator, delivering improved blood-glucose values and weight loss.
A Mayo Clinic study found that bariatric surgery reduces long-term cardiovascular risk more effectively than weight-loss medications. The study analyzed outcomes for 812 adults with obesity and found that greater weight loss led to larger reductions in lifetime cardiovascular risk.
A new analysis of nearly 400 young participants found that those starting a healthy lifestyle program in spring showed weaker improvement than those beginning in summer, autumn, or winter. The study suggests that school calendars, daily routines, and long holiday breaks can impact treatment success.
A preclinical study found that mice stopped and restarted GLP-1s gained less weight over time, with a significant decrease in muscle mass. The researchers suggest that clinicians help patients preserve muscle mass while on these medications through exercise or nutrition.
A 10-year study found that obesity leaves a lasting impact on the immune system, with helper T cells carrying a long memory of being overweight. This 'memory' can lead to ongoing risk of obesity-related conditions even after weight loss.
Researchers reveal how expansion of bone marrow fat promotes immunosuppressive PD-L1 signaling, leading to enhanced osteoclast activity and accelerated bone loss. Reducing bone marrow fat improves bone structure.
A new procedure, duodenal mucosal resurfacing, has shown promising results in preventing weight regain after GLP-1 therapy discontinuation. The study found that patients who underwent the procedure maintained over 80% of their weight loss and regained less weight compared to those who received a sham procedure.